Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | PLAU | P00749 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL561952 | 0.85 | TRPV1 (0.52) | KMT2AKDM4EPLAUHTTALDH1A1 | |
| SCHEMBL562451 | 0.79 | MEN1 (0.62) | KMT2AHTTALDH1A1ADORA3ADORA2A | |
| SCHEMBL9001653 | 0.77 | KMT2A (0.75) | KMT2AKDM4EPLAUHTTALDH1A1 | |
| SCHEMBL20897029 | 0.76 | HDAC4 (0.39) | PLAUHTTALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL2732912 | 0.76 | GRIA3 (0.46) | HTTALDH1A1CYP3A4CYP2C9ALOX12 | |
| SCHEMBL9001650 | 0.76 | MAOA (0.63) | KMT2AKDM4EPLAUHTTALDH1A1 | |
| SCHEMBL6984745 | 0.75 | HTT (0.57) | KMT2AKDM4EPLAUHTTALDH1A1 | |
| SCHEMBL9001647 | 0.75 | ATM (0.72) | KMT2AKDM4EPLAUHTTNPC1 | |
| SCHEMBL14333923 | 0.74 | PLAU (0.56) | KMT2AKDM4EPLAUHTTALDH1A1 | |
| SCHEMBL548490 | 0.73 | GRIA3 (0.56) | KMT2AKDM4EALDH1A1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240300931-A1 | Composition and Methods for Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2024-09-12 | — | — | US | claimed |
| US-20240100023-A1 | Compositions and Methods For Treating Spinal Cord Injuries | LIPPA ARNOLD S (US) | 2024-03-28 | — | — | US | claimed |
| US-20230373982-A1 | Compositions And Methods For Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2023-11-23 | — | — | US | claimed |
| US-20230129330-A1 | Compositions And Methods For Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2023-04-27 | — | — | US | claimed |
| US-20210340130-A1 | Compositions and methods for treating attention deficit disorders | LIPPA ARNOLD STAN (US) | 2021-11-04 | — | — | US | claimed |
| US-20190112300-A1 | Compositions And Methods For Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2019-04-18 | — | — | US | claimed |
| EP-2154970-B1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | RESPIRERX PHARMACEUTICALS INC (US) | 2017-10-25 | — | — | EP | claimed |
| US-8404682-B2 | Di-substituted amides for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | claimed |
| US-20120035173-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | RESPIRERX PHARMACEUTICALS INC | 2012-02-09 | — | — | US | claimed |
| US-8013003-B2 | Di-substituted amides for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2011-09-06 | — | — | US | claimed |
| US-20100120764-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | RESPIRERX PHARMACEUTICALS INC | 2010-05-13 | — | — | US | claimed |
| US-20240355686-A1 | Clinical Methods and Pharmaceutical Compositions Employing AMPA Receptor Antagonists to Treat Glioblastoma and Other Cancers | RADIN DANIEL PIERCE (US) | 2024-10-24 | — | — | US | disclosed |
| US-20240300931-A1 | Composition and Methods for Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2024-09-12 | — | — | US | disclosed |
| US-20240100023-A1 | Compositions and Methods For Treating Spinal Cord Injuries | LIPPA ARNOLD S (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230373982-A1 | Compositions And Methods For Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2023-11-23 | — | — | US | disclosed |
| US-20100120764-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | RESPIRERX PHARMACEUTICALS INC | 2010-05-13 | — | — | US | disclosed |
| US-20100120764-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | RESPIRERX PHARMACEUTICALS INC | 2010-05-13 | — | — | US | disclosed |
| EP-2154970-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008143963-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008143963-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340130-A1 | Compositions and methods for treating attention deficit disorders | GRIN2A, GRIN2C, GRM2 | KMT2A 1530/4885KDM4E 3925/4885PLAU 2476/4885 |
| US-20240100023-A1 | Compositions and Methods For Treating Spinal Cord Injuries | CHAT, NTRK2, GMFG | KMT2A 1985/4885KDM4E 4210/4885PLAU 1352/4885 |
| US-20230129330-A1 | Compositions And Methods For Treating Attention Deficit Disorders | GRIN2A, GRIN2C, GRM2 | KMT2A 1530/4885KDM4E 3925/4885PLAU 2476/4885 |
| US-20120035173-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | GRIN2A, GRIN2B, SLC18A2 | KMT2A 1571/4885KDM4E 1686/4885PLAU 4829/4885 |
| US-20100120764-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | DRD2, DRD3, GAP43 | KMT2A 1763/4885KDM4E 2026/4885PLAU 4735/4885 |
| US-20230373982-A1 | Compositions And Methods For Treating Attention Deficit Disorders | GRIN2A, GRIN2C, GRM2 | KMT2A 1530/4885KDM4E 3925/4885PLAU 2476/4885 |
| US-20240300931-A1 | Composition and Methods for Treating Attention Deficit Disorders | GRIN2A, GRIN2C, NTRK2 | KMT2A 1678/4885KDM4E 4047/4885PLAU 2313/4885 |
| US-20190112300-A1 | Compositions And Methods For Treating Attention Deficit Disorders | GRIN2A, GRIN2C, GRM2 | KMT2A 1530/4885KDM4E 3925/4885PLAU 2476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.